Trial Profile

A phase I study of AQ280 in healthy volunteers

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AQ 280 (Primary)
Indications Eosinophilic oesophagitis
Focus Adverse reactions
Acronyms ARIA-2

Most Recent Events

22 May 2025 New trial record
12 May 2025 According to an Aqilion media release, study is expected to be conducted in June in the US in healthy study participants and the results are expected after the summer.
12 May 2025 According to an Aqilion media release, company announces that US Food and Drug Administration (FDA) has approved IND (investigational new drug) application for the drug candidate AQ280.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com